Government proposes immediate suspension of manufacturing licences of substandard drugs
Summary
- The proposed amendment mandates immediate suspension of licences for manufacturers found producing substandard drugs.
- Suspension remains in force until the manufacturer implements prescribed corrective measures.
- Only after corrective actions are verified can the licence be reinstated; revocation follows if measures are not undertaken.
- The move aims to strengthen drug quality control and protect public health.
Key Facts
- · Immediate suspension of licences for substandard drug manufacturers.
- · Suspension continues until corrective action is taken.
- · Corrective measures are mandatory before any licence reinstatement.
- · Failure to comply may lead to permanent revocation of the licence.
- · The amendment is part of a broader effort to curb circulation of substandard medicines.
- · It aligns with WHO guidelines on drug safety and quality.
Why it matters
Ensuring the quality of medicines safeguards public health, enhances confidence in the healthcare system, and compels the pharmaceutical industry to adhere to stringent safety standards, thereby reducing morbidity and mortality caused by substandard drugs.
#drug safety#pharmaceutical regulation#public health#government policy#quality control